Showing results (51-60 of 5,175) with videos related to
Sort By:
Pageof 518
The Prostate|March 8, 2012
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancerJohn T Isaacs, Jason M D'Antonio, Shuangling Chen, et al.The Annals of Pharmacotherapy|July 31, 2008
Left posterior fascicular block due to high-dose interleukin-2Anand Singla, Samuel R DenmeadeThe Prostate|November 23, 2005
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrugSamuel Janssen, D Marc Rosen, Rebecca M Ricklis, et al.Journal of the National Cancer Institute|July 3, 2003
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancerSamuel R Denmeade, Carsten M Jakobsen, Samuel Janssen, et al.The Prostate|January 23, 2003
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer modelsSamuel R Denmeade, Lori J Sokoll, Susan Dalrymple, et al.Cancer Research|June 19, 2021
Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?Laura A Sena, Samuel R DenmeadeBioorganic & Medicinal Chemistry|January 18, 2006
Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cellsHelmer Søhoel, Anne-Marie Lund Jensen, Jesper V Møller, et al.Molecular Cancer Therapeutics|December 25, 2014
Protease-activated pore-forming peptides for the treatment and imaging of prostate cancerAaron M LeBeau, Samuel R DenmeadeThe Prostate|August 29, 2000
In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenograftsS R Khan, S R DenmeadeAnnals of Clinical Biochemistry|March 1, 1994
Neonatal screening for phenylketonuria: evaluation of an automated enzymatic methodS Keffler, R Denmeade, A GreenPageof 518